As aforementioned, combined blockage of MEK+BCL-XL/BCL2 is currently explored in two clinical trials, for patients with advanced or metastatic solid tumors, and with recurrent ovarian and endometrial cancers. This evidence concerns the gene BCL2 and endometrial cancer.